DoD awards PureTech $11.4M to advance LYT-300 for FXTAS treatment

PureTech Health announced that the company has been awarded up to $11.4Mfrom the U.S. Department of Defense to advance its therapeutic candidate, LYT-300,oral allopregnanolone , for the treatment of Fragile X-associated Tremor Ataxia Syndrome FXTAS . The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis..”FXTAS is a devastating, late-onset neurodegenerative condition characterized by cognitive decline, tremors in the hands and balance problems. Currently, there are no primary treatments for FXTAS, though IV-administrated allopregnanolone has demonstrated therapeutic potential,” said Dr. Randi Hagerman, M.D., F.A.A.P., Medical Director of the UC Davis MIND Institute, Chair in Fragile X Research and co-primary investigator for the LYT-300 trial. “This award from the DoD allows us to expand our evaluation of LYT-300, a candidate with a wide variety of potential indications, into FXTAS, an area of tremendous need where otherwise normally developed, aging individuals suffer from significant neurodegeneration,” said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech Health. “We look forward to collaborating with Dr. Randi Hagerman and her team at UC Davis to bring the potential of allopregnanolone to the thousands of individuals with FXTAS in need of a treatment.”